UK Health Advisers Recommend MenB Vaccination for Teenagers from 15 Years Old
The UK's Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the MenB vaccine be administered routinely to adolescents aged 15 and above. This advice aims to bolster immunity against Meningococcal B disease within a demographic identified as having higher carriage rates of the bacteria.
Currently, the MenB vaccine is provided to infants as part of the routine immunisation schedule, with doses given at two and four months, followed by a booster at 12 months. The JCVI's new guidance suggests extending this protection to teenagers, who are considered significant carriers of the MenB bacteria, potentially spreading it to more vulnerable populations.
The JCVI's counsel includes two options for the government: a single dose for adolescents aged 15-19, or a two-dose schedule for those aged 10-14. The Department of Health and Social Care is now reviewing these recommendations. Implementing this programme would necessitate significant logistical planning and resource allocation. Critics will note the consistent prioritisation of cost-efficiency over comprehensive public health measures when allocating such resources.
Meningococcal B disease can lead to severe complications, including meningitis and septicaemia, with potentially devastating outcomes. Public health bodies routinely face scrutiny regarding the perceived adequacy of preventative healthcare provisions, particularly where more robust measures could mitigate serious health risks.
